Eun Yang
Stock Analyst at Jefferies
(0.72)
# 3,290
Out of 4,667 analysts
50
Total ratings
40%
Success rate
-22.69%
Average return
Main Sectors:
Stocks Rated by Eun Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UTHR United Therapeutics | Maintains: Buy | $315 → $432 | $366.24 | +17.96% | 8 | Sep 23, 2024 | |
| AVTE Aerovate Therapeutics | Downgrades: Hold | $65 → $2 | $2.61 | -23.37% | 3 | Jun 17, 2024 | |
| TSHA Taysha Gene Therapies | Assumes: Buy | $2 → $8 | $2.04 | +292.16% | 2 | May 14, 2024 | |
| ATXS Astria Therapeutics | Maintains: Buy | $22 → $27 | $9.61 | +180.96% | 2 | Mar 25, 2024 | |
| RLYB Rallybio | Downgrades: Hold | $7 → $1.5 | $1.02 | +47.06% | 2 | Feb 7, 2024 | |
| BBIO BridgeBio Pharma | Downgrades: Hold | $24 → $33 | $23.50 | +40.43% | 1 | Jul 18, 2023 | |
| BMEA Biomea Fusion | Downgrades: Hold | $36 → $28 | $6.27 | +346.57% | 2 | Jun 26, 2023 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $27 | $25.75 | +4.85% | 1 | Mar 29, 2023 | |
| GNSS Genasys | Maintains: Outperform | $6 → $7 | $3.80 | +84.21% | 1 | Feb 10, 2023 | |
| CVAC CureVac | Upgrades: Buy | n/a | $2.51 | - | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $17 → $7 | $4.34 | +61.29% | 3 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $2.98 | +740.34% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $525 → $75 | $1.28 | +5,759.38% | 1 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $84 | $96.11 | -12.60% | 3 | Aug 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $2.08 | +1,104.82% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $4.59 | - | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $16.96 | +106.37% | 1 | Jun 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $220 | $288.55 | -23.76% | 3 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $38 → $31 | $19.06 | +62.64% | 5 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $2.75 | +14,445.45% | 1 | Jul 24, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $310 | $157.18 | +97.23% | 3 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $80 | $89.23 | -10.34% | 3 | Jul 11, 2017 |
United Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $315 → $432
Current: $366.24
Upside: +17.96%
Aerovate Therapeutics
Jun 17, 2024
Downgrades: Hold
Price Target: $65 → $2
Current: $2.61
Upside: -23.37%
Taysha Gene Therapies
May 14, 2024
Assumes: Buy
Price Target: $2 → $8
Current: $2.04
Upside: +292.16%
Astria Therapeutics
Mar 25, 2024
Maintains: Buy
Price Target: $22 → $27
Current: $9.61
Upside: +180.96%
Rallybio
Feb 7, 2024
Downgrades: Hold
Price Target: $7 → $1.5
Current: $1.02
Upside: +47.06%
BridgeBio Pharma
Jul 18, 2023
Downgrades: Hold
Price Target: $24 → $33
Current: $23.50
Upside: +40.43%
Biomea Fusion
Jun 26, 2023
Downgrades: Hold
Price Target: $36 → $28
Current: $6.27
Upside: +346.57%
Enliven Therapeutics
Mar 29, 2023
Initiates: Buy
Price Target: $27
Current: $25.75
Upside: +4.85%
Genasys
Feb 10, 2023
Maintains: Outperform
Price Target: $6 → $7
Current: $3.80
Upside: +84.21%
CureVac
Jan 9, 2023
Upgrades: Buy
Price Target: n/a
Current: $2.51
Upside: -
Dec 8, 2022
Downgrades: Hold
Price Target: $17 → $7
Current: $4.34
Upside: +61.29%
Nov 14, 2022
Initiates: Buy
Price Target: $25
Current: $2.98
Upside: +740.34%
Sep 22, 2022
Maintains: Buy
Price Target: $525 → $75
Current: $1.28
Upside: +5,759.38%
Aug 22, 2022
Maintains: Buy
Price Target: $78 → $84
Current: $96.11
Upside: -12.60%
Nov 2, 2021
Initiates: Buy
Price Target: $25
Current: $2.08
Upside: +1,104.82%
Jul 12, 2021
Initiates: Buy
Price Target: n/a
Current: $4.59
Upside: -
Jun 22, 2021
Initiates: Buy
Price Target: $35
Current: $16.96
Upside: +106.37%
Jul 27, 2018
Maintains: Buy
Price Target: $200 → $220
Current: $288.55
Upside: -23.76%
Nov 3, 2017
Maintains: Hold
Price Target: $38 → $31
Current: $19.06
Upside: +62.64%
Jul 24, 2017
Initiates: Buy
Price Target: $400
Current: $2.75
Upside: +14,445.45%
Jul 11, 2017
Assumes: Hold
Price Target: $310
Current: $157.18
Upside: +97.23%
Jul 11, 2017
Assumes: Hold
Price Target: $80
Current: $89.23
Upside: -10.34%